Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 1
2020 2
2021 7
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Harnessing the immune response to target tumors.
Manning L, Nemunaitis J. Manning L, et al. F1000Res. 2017 May 18;6:710. doi: 10.12688/f1000research.10795.1. eCollection 2017. F1000Res. 2017. PMID: 28620466 Free PMC article. Review.
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Gogineni V, et al. Among authors: manning l. J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021. J Cancer. 2021. PMID: 33391401 Free PMC article. Review.
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P, Ghisoli M, Crompton BD, Klega KS, Wexler LH, Slotkin EK, Stanbery L, Manning L, Wallraven G, Manley M, Horvath S, Bognar E, Nemunaitis J. Anderson P, et al. Among authors: manning l. Clin Cancer Res. 2023 May 1;29(9):1689-1697. doi: 10.1158/1078-0432.CCR-22-2292. Clin Cancer Res. 2023. PMID: 36780200 Free PMC article.
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: manning l. Cancer Gene Ther. 2022 Mar;29(3-4):369-382. doi: 10.1038/s41417-021-00317-5. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753870 Clinical Trial.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: manning l. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A, Rocconi RP, Monk BJ, Herzog TJ, Manning L, Bognar E, Wallraven G, Aaron P, Horvath S, Tang M, Stanbery L, Coleman RL, Nemunaitis J. Walter A, et al. Among authors: manning l. Gynecol Oncol. 2021 Dec;163(3):459-464. doi: 10.1016/j.ygyno.2021.10.004. Epub 2021 Oct 23. Gynecol Oncol. 2021. PMID: 34702567 Free article.
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rocconi RP, Stanbery L, Tang M, Walter A, Monk BJ, Herzog TJ, Coleman RL, Manning L, Wallraven G, Horvath S, Bognar E, Senzer N, Brun S, Nemunaitis J. Rocconi RP, et al. Among authors: manning l. Commun Med (Lond). 2022 Aug 29;2:106. doi: 10.1038/s43856-022-00163-y. eCollection 2022. Commun Med (Lond). 2022. PMID: 36051466 Free PMC article.
17 results